A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowing Treatment in Chinese Participants
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Atorvastatin/ezetimibe (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 13 Feb 2019 Planned End Date changed from 12 Mar 2021 to 26 Feb 2021.
- 13 Feb 2019 Planned primary completion date changed from 28 Feb 2021 to 18 Dec 2020.
- 13 Feb 2019 Planned initiation date changed from 28 May 2019 to 14 May 2019.